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Adel de Klerk, Emmerentia van Schalkwyk, Zelda Williams, 
Wendy Lee, Philip Bardin 
Background and objectives. To evaluate risk factors for asthma 
death such as access to health care, over-use of P2-agonists 
or under-use of inhaled corticosteroids in the Western Cape 
(WC) population, using near-fatal asthma (NFA) as a 
surrogate marker. 
Subjects and methods. Patients with NFA (cases) admitted to 
a WC teaching hospital were compared with patients with 
acute asthma in a case-control study using a structured 
questionnaire, clinical examination, arterial blood gas 
measurements, chest radiograph and pulmonary function 
measurements. 
Results. Sixteen patientswithNFA (cases) and 55 with acute 
asthma (controls) were prospectively enrolled. Duration of 
asthma, gender, smoking status and ethnicity were similar. 
Cases had significantly more previous mechanical 
ventilation (P < 0.05) and a trend towards more previous 
intensive care unit (ICU) admissions. No significant 
differences were found ln primary health care variables. 
Conclusion. Our study demonstrates that patients with NFA 
constitute a significant number of emergency room (ER) 
.admissions for acute asthma (30%) in our population. 
Similar to other studies, there was a trend for NFA toward 
more previous ICU admissions and mechanical ventilatiOn. 
Relative under-use of Pragonists the day before admission 
and fewer ER visits during the previous. year in th.e NFA 
group, suggests an impaired perception of the severity of 
disease or a more rapid onset of symptoms. Negative 
factors such as inability to access health care or lack of 
medication supply were similar in both groups. The 
challenge remains to identify and manage high-risk patients 
effectively. 
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Rising asthma morbidity and mortality rates are experienced 
internationally despite increased understanding of the 
pathogenesis of asthma and the development of new treatment 
modalities.1-4 Over the past 3 years (ldmission rates for patients 
with severe life-threatening asthma to the Tygerberg Hospital 
Respiratory Intensive Care Unit have increased substantially 
(P Bardin - personal communication). 
Near-fatal asthma (NFA) is used as a validated surrogate 
marker for patients at risk of fatal asthma on the assumption 
that they share similar pathophysiological mechanisms.1"-' This 
assumption provides physiological and biochemical data that 
can provide clues to the pathophysiology of asthma deaths. To 
reduce the incidence of NFA and asthma deaths it is essential 
to identify fatality-prone subjects, recognise life-threatening 
features (e.g. respiratory arrest or coma, or severe dyspnoea 
with a silent chest) and to understand the pathophysiology 
(e.g. severe airway obstruction and alteration of the acid-base 
status). NFA is defined as respiratory arrest caused by acute 
asthma, or acute asthma with an arterial carbon dioxide 
tension (PaC02) greater than 6 kPa and/ or an altered state of 
consciousness.'-1' 
Several risk and precipitating factors for NFA have been 
identified in previous studies. They include marked diurnal 
variations in peak expiratory flow (PEF),15-1' worsening of 
asthma over 2 - 7 days before admission,1' young people,20•21 
smoking,22-23 allergens," respiratory infections, atopy" and 
chronic use of f3z-agonists.''-34 Other factors may also be 
important, in particular geographical location, but this has not 
been assessed in the Western Cape. 
Previous studies on risk factors for NFA were mostly done in 
developed countries. Only one study addressing some of these 
risks in patients in South Africa has previously been published, 
by Kallenbach et al." They identified attack duration and 
under-treatment as risk factors in the 81 Johannesburg-based 
patients they studied. In the present study we planned to 
identify the risk factors for NFA in our Western Cape 
population. Primary risk factors evaluated were access to 
health care, relative over-use of Pz-agonists, under-use of 
inhaled corticosteroids, previous history of mechanical 
ventilation and admission to the intensive care unit (ICU) for 
severe acute asthma. Our results show that up to 30% of 
admissions meet criteria for NFA. Risk factors for NFA in our 
population are similar to those identified in other countries. 
METHODS 
All patients admitted to Tygerberg Hospital with the diagnosis 
of acute asthma were prospectively identified for 12 months 
from September 1999 to August 2000. Patients who met our 
a priori case definition for NFA (PaC02 > 6 kPa or intubation 
and ventilation before or during admission) were classified as 
subjects with NFA. Hospitalised patients with acute severe 
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asthma were used as the control group. Patients between 18 
and 45 years old with a confirmed diagnosis of asthma were 
eligible and diagnosis was based on criteria used by the 
American Thoracic Society.35 
Clinical and demographic data were obtained through the 
use of a structured questionnaire during a personal interview. 
Data obtained included duration of asthma, previous history of 
NFA, duration of current attack, prescribed therapy and access 
to health care. Smoking status, occupational history and 
precipitating factors were also noted, as well as arterial blood 
gas measurements, chest radiograph reports and 
electrocardiogram (ECG) results. Peak expiratory flow rates 
were measured on admission. Skin-prick testing was done 
employing a panel of common allergens. A reaction of > 3 mm 
to one or more allergens was defined as a positive result. All 
patients gave informed consent for a study protocol approved 
by the University of Stellenbosch-Tygerberg Hospital Ethical 
Committee. 
Analysis of data 
Data were analysed using MS Office-based spreadsheets and 
statistical tools. Subjects were grouped and analysed as NFA 
cases and controls. Risk factor analyses were based on sample 
sizes comparable to published studies.19•36•37 Descriptive statistics 
were calculated using pivot (contingency) tables. Means and 
standard deviations (where appropriate, otherwise ranges) 
were calculated for continuous variables. Trends were 
examined using percentages. Where suggested by the data, 
comparisons between groups were made using the Mann-
Whitney U-test (continuous .data) and chi-square test 
(categorical data). Statistical significance was accepted at a 
level of P < 0.05. 
RESULTS 
Approximately 230 patients between 18 and 45 years old were 
admitted to the emergency room (ER) with the diagnosis of 
acute asthma in the 12-month period fron;i 1September1999 to 
31 August 2000. For logistical reasons (availability of staff, 
w1~ekends and holidays excluded, etc.) we enrolled 71 patients 
into our study during this period, 16 as cases of NFA and 55 in 
the control group with acute severe asthma. There was no clear 
seasonal pattern observed (Fig. 1). There were 3 deaths in the 
NFA group. Two deaths were as a result of ICU-related sepsis 
and 1 death followed a spontaneous pneumothorax. There was 
no significant difference between the case and control groups 
with regard to demographic variables, smoking status, 
employment or duration of asthma (Table I). Cases were more 
likely than controls to have had a history of previous 
pulmonary tuberculosis (PTB) according to the patient (not 
diagnosed on chest radiograph (CXR)) (P < 0.05). Cases had 
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Fig. 1. Month of admission. 
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Table I. Clinical and demographic characteristics 
Cases (N = 16) Controls (N"' 55 ) 
Age (years) 
Gender (N (%)) 
Male 
Female 
33.75 ± 7.64 31.67 ± 9.70 












Non-smokers 6 (37.5) 
Ex-smokers 7 (43.75) 
Current smokers 3 (18.75) 
Pack-years (SD) 2.3 (3.64) 
Occupational status: employed 10 (62.5) 
(N(%)) 
Duration of asthma (years) 
Previous PTB (N (%)) 
18.91 ± 14.29 
4 (26.67)* 
History of severe asthma (N (%)) 
ER visitst 11 (73) 
Hospital admissionst 8 (53) 
ICU admissions 8 (53) 


















Data presented as means ± standard deviation (SD) unless stated otherwise. 
'P< 0.05. 
t = Previous 12 months. 
PTB = pulmonary tuberculosis; ER =emergency room; ICU = intensive care unit. 
controls (53% versus 18.5%, P = 0.02). There was a trend for 
cases towards more prior ICU admissions (53% versus 24%, P 
= 0.062). ER visits (73% versus 81 %, P = 0.38) and hospital 
admissions (53% versus 70.4%, P = 0.35) did not differ 
significantly. 
Clinical characteristics, CXR findings, arterial blood gas 
measurements and medication use by the study subjects are 
presented in Table II. Cases were more likely than controls to 
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Table II. Admission characteristics (data presented as means ;1: standard deviation unless stated otherwise) 
Heart rate (beats/min) 
Respiratory rate (breaths/min) 
Accessory muscle use (N (%)) 
Altered level of consciousness (N (%)) 
Chest radiograph (N (%)) 
Normal 
Abnormalt 




Cases (N = 16) 
109.5 ± 26.2 






7.34 ± 4.19 
Controls (N = 55) 
102.1±18.8 






4.5 ± 0.92 
Er-agonists (µg/day) 
Usually 
24 hours before admission 
Inhaled corticosteroids (µg/ day) 
Prescribed 
257.14 ± 217.37 
761.53 ± 531.56* 
312.96 ± 293.99 
1 315.21 ± 1 881.01 
Taken past 2 weeks 
Oral corticosteroids (mg/ day) 
Theophyllin (N (%)) 
• P<0.05. 
t Abnormalities consistent with fibrosis and other mild structural abnormalities. 
1 800 
546.66 ± 551.44 




~ 1400 f 















....._ Dose taken 24 hours before admission 
(control) 
Fig. 2. Mean dose of inhaled f3ragonist taken 24 hours before 
admission (P < 0.05). 
present with an altered level of consciousness (P = 0.015). The 
mean daily dose of inhaled f3z-agonist taken in response to 
exacerbations is shown in Fig. 2. Controls used significantly 
larger doses of f3z-agonists in the 24 hours before admission 
(761.53 µg versus 1 315.2 µg, P = 0.027). Peak flow 
measurements done during admission to the ER did not differ 
between cases and controls (Table III). 
Table Ill. Peak flow measurements during emergency room 





Cases (N = 10) 
33.3 ± 19.8 
54.21±37.0 
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Controls (N = 55) 
40.15 ± 127.6 
59.08 ± 92.0 
495.83 ± 414.60 
582.60 ± 659.73 
22.25 ± 18.55 
39 (70.09) 
There were no significant differences in primary health care 
variables between cases and controls (Table IV). In the NFA 
group, however, 3 of 16 patients (18.75%) waited more than 2 
hours before they were seen by a doctor, compared with 4 of 55 
(7.27%) in the control group. 
Table IV. Primary health care variables 
Cases (N = 16) Controls (N = 55) 
Primary care facility (N (%)) 
Tygerberg Hospital 3 (18.75) 9 (16.36) 
Day hospital/regional hospital 8 (50.0) 26 (47.27) 
Medication (N (%)) 
Supply exhausted 12 (75.0) 33 (60.0) 
Adequate supply given at facility 4 (25.0) 23 (41.8) 
Time before medical attention 
sought> 24 hours (N (%)) 5 (31.25) 7 (12.75) 
Transport to medical facility 
(N(%)) 
Self 9 (56.25) 33 (60.0) 
Other 7 (43.75) 22(40.0) 
Time before seen by doctor (N (%)) 
Immediately 10 (62.5) 36 (65.45) 
After > 2 hours 3 (18.75) 4 (7.27) 
DISCUSSION 
We used a case-control study of hospitalised patients with 
asthma to identify risk factors for NFA. Our findings confirmed 
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the results of previous work, suggesting that a history of prior 
ICU admissions and mechanical ventilation are predictors of 
life-threatening asthma. Moreover, we identified a relative 
under-use of Pz-agonists as well as fewer ER visits in the 12 
months before admission in patients with NFA. No difference 
was noted for access to health care and other primary health 
care evaluations. 
The final pathway leading to death in patients with acute 
severe asthma has not been clarified. It is clear that several risk 
factors may be important in this process and that this may vary 
in different areas and populations. We assessed the importance 
of risk factors for asthma death using a validated surrogate 
marker, NFA, in the Western Cape, with a different population 
to that found in westernised, First-World countries and 
environments. In general, our observations were similar to 
those found in studies in Canada and other countries.19•38•39 We 
assessed age, gender, smoking habits, social factors, 
environmental conditions and use of medication in the control 
and NFA groups. There were no significant differences, 
although a number of variations were observed. This included 
lower doses of inhaled P2-agonists in the day before admission 
in the NFA group. 
Several studies have reported an association between the use 
of inhaled p2-agonists and asthma death,39" 0 especially in the 
absence of inhaled corticosteroids.'1•43 The risk was particularly 
high in subjects who reported a rapid increase in Pz-agonist 
use. In this study the NFA group used less bronchodilator 
treatment for 24 hours before admission, suggesting that they 
had either exhausted their supply or required less medication. 
This in turn implies that their perception of dyspnoea may be 
impaired, or a more rapid onset of symptoms in this group 
given the severity of the asthma attack as judged on admission. 
Good evidence exists to show a reduced ability to perceive life-
threatening airway obstruction in some asthmatics, particularly 
males.44-46 Our observations are similar to those reported by 
Turner and co-workers,19 who found a similar difference. 
Furthermore, there was a lower rate of ER admissions 
compared with the prior 12 months in the NFA group, also 
suggesting an inability-to judge the severity of acute asthma in 
this group. 
Because of social instability, poverty and a perceived lack of 
access to health care, we analysed social and other factors as 
possible risk factors. Surprisingly, there was no indication that 
NFA was associated with an inability to access health care or a 
lack of supply of medication. However, it is likely that such 
negative factors had an influence across both groups and 
future studies must assess differences in asthmatics seen in 
other hospitals, areas and situations. There was also no 
difference in the use of various treatments, particularly inhaled 
and oral corticosteroids, risk factors identified in other 
studies. 47'48 
The absence of external factors that appear to predispose 
asthmatics to severe asthma is not entirely surprising. Recent 
evidence has suggested that a primary determinant of severity 
is likely to be related to the asthmatic phenotype itself. 
Coupled with genetic influences, asthmatics may have an 
inability to control and repair allergic inflammatory responses 
that may be independent of outside factors. 49 In acute asthma 
there may be an important exception - the cause of the 
exacerbation - and in this situation, certain viruses may be the 
trigger for very severe asthma as a result of their inflammatory 
actions and consequences. 
The finding of a history of previous PTB in the NFA group 
might be important. Although the diagnosis was subjective, 
this might indicate the detrimental effects of previous 
structural lung damage . 
A potential criticism of any study such as this one is always 
in the selection of a control group. We selected hospitalised 
patients with asthma as a control group to isolate variables of 
interest: risk factors for NFA in severely asthmatic individuals. 
Because most community asthma patients would never be 
hospitalised, their inclusion could increase the magnitude of 
association for NFA risk factors. However, a three-way 
comparison between groups would enhance the ability to 
discern the effect of hospitalisation itself as a factor. 
In conclusion, our study in the Western Cape, the first in 
South Africa to evaluate NFA risk factors prospectively, 
suggests that the NFA group contributes a significant number 
of ER admissions for acute asthma. NFA was associated with 
significantly more mechanical ventilation and a trend towards 
more ICU admissions. Patients with NFA also used 
significantly less Pz-agonists before admission. Although 
guidelines designed to improve asthma management have 
been published,42" 0•51 the challenge remains to identify high-risk 
patients and to implement these recommendations. In order to 
realise this goal an effective asthma education 'strategy, aimed 
at patients and physicians, will be crucial in future. 
We thank the patients who participated in the study, the 
nursing staff of Ward F1, Tygerberg Hospital, and the doctors 
who helped with patient management, for their support. 
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WHAT IS WRONG WITH MY 
PATIENT? HOW TO READ AN 
ARTICLE CONCERNING 
DIAGNOSIS 
P Rheeder, J A Ker 
Two critically important questions arise from the doctor-patient 
encounter. Firstly, given the patient's profile (demography, 
signs and symptoms), what is the most likely diagnosis, and 
secondly given the diagnosis what is the most effective 
intervention? 
Diagnostic reasoning skills are vital for effective patient care. 
The basis of these skills should be sound diagnostic research on 
the appropriate signs, symptoms and tests regarding a 
particular disease. Diagnostic research has undergone 
significant developments during the last number of years. 
Some of these principles are common knowledge while others 
are poorly understood. Given that diagnostic knowledge is 
vital for patient care it is imperative that the practising 
physician should be able to appraise articles on diagnostic 
research critically. 
The development of diagnostic research has been a stepwise 
refinement of concepts (Fig.1). 
Prediction rules Sensitivity and specificity 
t 
I ROC curves I Predictive values 
'I~ __ L_ik_e_li_h_o_o_d_r_a_ti_os __ , / 
Fig. 1. Progressive steps in diagnostic research. 
STEPS IN DIAGNOSTIC RESEARCH 
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